Table 1.
Supplementary clinical information of PDOs donor.
| Sample ID | Tumor stage | Type of treatments | Clinical outcome | Mutation | ||
|---|---|---|---|---|---|---|
| KRas | Nras | Braf | ||||
| P1 | T3N0M0 | Surgery | Survival | Wild | Wild | Wild |
| P2 | T3N2M0 | Postoperative chemotherapy (XELOX) | Survival | Wild | Wild | Wild |
| P3 | T3N0M0 | Surgery | Survival | Not detected | Not detected | Not detected |
| P4 | T3N1M1 | mFOLFOX6 + cetuxima, liver metastases resection, postoperative chemotherapy (XELOX) | Recurrence | Wild | Wild | Wild |
| P5 | T3N1M1 | FOLFOX, liver metastases resection, Postoperative chemotherapy (XELOX) | Survival | exon 2 mutation | Wild | Wild |
| P6 | T4N1M1 | mFOLFOX6, liver metastases resection, Postoperative chemotherapy (XELOX) | Recurrence | exon 2 mutation | Wild | Wild |
| P7 | T3N1M0 | Postoperative chemotherapy (XELOX) | Survival | Wild | Wild | Wild |
| P8 | T3N1M0 | Postoperative chemotherapy (XELOX) | Survival | Not detected | Not detected | Not detected |
| P9 | T3N0M0 | Surgery | Survival | Wild | Wild | Wild |
| P10 | T3N0M0 | Surgery | Survival | Not detected | Not detected | Not detected |
| P11 | T3N1M0 | Postoperative chemotherapy (XELOX) | Survival | Wild | Wild | Wild |
| P12 | T3N1M0 | Postoperative chemotherapy (XELOX) | Survival | exon 2 mutation | Wild | Wild |
| P13 | T3N1M0 | Postoperative chemotherapy (XELOX) | Survival | Not detected | Not detected | Not detected |
| P14 | T3N1M0 | Postoperative chemotherapy (XELOX) | Survival | Not detected | Not detected | Not detected |